# GKOS catalysts: GLAUKOS Corp PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/gkos/catalysts

> GLAUKOS Corp (GKOS) has 6 upcoming catalysts. The next is the glk-221 ophthalmic solution primary completion, April 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | GLAUKOS Corp |
| Ticker | GKOS (NYSE) |
| SEC CIK | 1192448 |
| SIC | 3841 |
| SEC filings | https://sec-api.dev/companies/gkos |

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| April 15, 2016 | [Photrexa Viscous In Dextran 20% (riboflavin 5'-phosphate; riboflavin 5'-phosphate sodium) FDA approval](https://sec-api.dev/pdufa/riboflavin-5-riboflavin-5) | GKOS |  | completed, approved | "NDA203324 ORIG-1 (Type 3 - New Dosage Form): submission_status AP, submission_status_date 20160415, review_priority PRIORITY; sponsor_name GLAUKOS; product PHOTREXA VISCOUS IN DEXTRAN 20% (RIBOFLAVIN 5'-PHOSPHATE; RIBOFLAVIN 5'-PHOSPHATE SODIUM)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA203324%22)) |
| July 15, 2016 | [Photrexa Viscous In Dextran 20% (riboflavin 5'-phosphate; riboflavin 5'-phosphate sodium) FDA approval](https://sec-api.dev/pdufa/riboflavin-5-riboflavin-5) | GKOS |  | completed, approved | "NDA203324 ORIG-2 (Efficacy): submission_status AP, submission_status_date 20160715, review_priority PRIORITY; sponsor_name GLAUKOS; product PHOTREXA VISCOUS IN DEXTRAN 20% (RIBOFLAVIN 5'-PHOSPHATE; RIBOFLAVIN 5'-PHOSPHATE SODIUM)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA203324%22)) |
| December 13, 2023 | [Idose Tr (travoprost) FDA approval](https://sec-api.dev/pdufa/travoprost) | GKOS |  | completed, approved | "NDA218010 ORIG-1 (Type 3 - New Dosage Form): submission_status AP, submission_status_date 20231213, review_priority STANDARD; sponsor_name GLAUKOS; product IDOSE TR (TRAVOPROST)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA218010%22)) |
| October 17, 2025 | [Epioxa Hd/Epioxa Kit (riboflavin 5'-phosphate sodium) FDA approval](https://sec-api.dev/pdufa/riboflavin-5) | GKOS |  | completed, approved | "NDA219910 ORIG-1 (Type 5 - New Formulation or New Manufacturer): submission_status AP, submission_status_date 20251017, review_priority STANDARD; sponsor_name GLAUKOS; product EPIOXA HD/EPIOXA KIT (RIBOFLAVIN 5'-PHOSPHATE SODIUM)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA219910%22)) |
| December 2025 | [Lufepirsen high dose primary completion](https://sec-api.dev/pdufa/lufepirsen) | GKOS | Persistent Corneal Epithelial Defect | delayed | "NCT05966493 (A Study to Evaluate the Safety and Efficacy of NEXAGON® (Lufepirsen Ophthalmic Gel) in Subjects With PCED): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2025-12 (ESTIMATED); Lead Sponsor Glaukos Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05966493)) |
| January 27, 2026 | [Idose Tr (travoprost) label expansion decision](https://sec-api.dev/pdufa/travoprost) | GKOS |  | completed, approved | "NDA218010 SUPPL-4 (Efficacy): submission_status AP, submission_status_date 20260127, review_priority STANDARD; sponsor_name GLAUKOS; product IDOSE TR (TRAVOPROST)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA218010%22)) |
| September 2026 | [Glk-321 low dose bid primary completion](https://sec-api.dev/pdufa/glk-321-low) | GKOS | Demodex Blepharitis | delayed | "NCT07400965 (Evaluation of the Safety and Efficacy of GLK-321 in Subjects With Demodex Blepharitis): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-09 (ESTIMATED); Lead Sponsor Glaukos Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07400965)) |
| Sep to Dec 2026 | [Glk-321 low dose bid topline data readout](https://sec-api.dev/pdufa/glk-321-low) | GKOS | Demodex Blepharitis | scheduled | "NCT07400965 (Evaluation of the Safety and Efficacy of GLK-321 in Subjects With Demodex Blepharitis): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-09 (ESTIMATED); Lead Sponsor Glaukos Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07400965)) |
| April 2027 | [Glk-221 ophthalmic solution primary completion](https://sec-api.dev/pdufa/glk-221) | GKOS | Keratoconus | scheduled | "NCT07400952 (Placebo-controlled Study to Evaluate the Safety and Efficacy of GLK-221 Ophthalmic Solution in Subjects With Keratoconus): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-04 (ESTIMATED); Lead Sponsor Glaukos Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07400952)) |
| Apr to Jul 2027 | [Glk-221 ophthalmic solution topline data readout](https://sec-api.dev/pdufa/glk-221) | GKOS | Keratoconus | scheduled | "NCT07400952 (Placebo-controlled Study to Evaluate the Safety and Efficacy of GLK-221 Ophthalmic Solution in Subjects With Keratoconus): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-04 (ESTIMATED); Lead Sponsor Glaukos Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07400952)) |
| March 2028 | [Gen 2 travoprost intracameral implant primary completion](https://sec-api.dev/pdufa/gen-2-travoprost-intracameral-implant) | GKOS | Glaucoma | scheduled | "NCT07075718 (Phase 2 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-03 (ESTIMATED); Lead Sponsor Glaukos Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07075718)) |
| Mar to Jun 2028 | [Gen 2 travoprost intracameral implant topline data readout](https://sec-api.dev/pdufa/gen-2-travoprost-intracameral-implant) | GKOS | Glaucoma | scheduled | "NCT07075718 (Phase 2 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-03 (ESTIMATED); Lead Sponsor Glaukos Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07075718)) |
| June 2028 | [Gen 2 travoprost intracameral implant primary completion](https://sec-api.dev/pdufa/gen-2-travoprost-intracameral-implant) | GKOS | Glaucoma | scheduled | "NCT07495852 (Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-06 (ESTIMATED); Lead Sponsor Glaukos Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07495852)) |
| Jun to Sep 2028 | [Gen 2 travoprost intracameral implant topline data readout](https://sec-api.dev/pdufa/gen-2-travoprost-intracameral-implant) | GKOS | Glaucoma | scheduled | "NCT07495852 (Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-06 (ESTIMATED); Lead Sponsor Glaukos Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07495852)) |

## Drugs

- [Gen 2 travoprost intracameral implant](https://sec-api.dev/pdufa/gen-2-travoprost-intracameral-implant): Glaucoma
- [Glk-221 ophthalmic solution](https://sec-api.dev/pdufa/glk-221): Keratoconus
- [Glk-321 low dose bid](https://sec-api.dev/pdufa/glk-321-low): Demodex Blepharitis
- [Lufepirsen high dose](https://sec-api.dev/pdufa/lufepirsen): Persistent Corneal Epithelial Defect
- [Epioxa Hd/Epioxa Kit (riboflavin 5'-phosphate sodium)](https://sec-api.dev/pdufa/riboflavin-5): 
- [Photrexa Viscous In Dextran 20% (riboflavin 5'-phosphate; riboflavin 5'-phosphate sodium)](https://sec-api.dev/pdufa/riboflavin-5-riboflavin-5): 
- [Idose Tr (travoprost)](https://sec-api.dev/pdufa/travoprost): 

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/gkos/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "GKOS catalysts: GLAUKOS Corp PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/gkos/catalysts

```bibtex
@misc{secapidev_companies_gkos_catalysts_20261116,
  title        = {GKOS catalysts: GLAUKOS Corp PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/gkos/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_gkos_catalysts_20261116","title":"GKOS catalysts: GLAUKOS Corp PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/gkos/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
